INDEX

	Paragraph	Page
ABC-M8 Chemical Agent Detector Paper	1-8	1-3
AC. (*See* Hydrogen cyanide.)		
Acetylcholine	1-4, 2-4*a*, 2-8*a*, 2-19*a*, 3-1*c*	1-2, 2-2, 2-9, 2-16, 3-1
Aerosols	1-3, 1-8*b*, 7-1 and -3, 7-9	1-1, 1-4, 7-1, 7-4
Air, land, and naval operations, disposal of contaminated clothing and equipment	B-5	B-1
Airtight plastic bags	B-5	B-1
Airway obstruction, treatment	2-4*c* and *g*, 2-6*e*, 2-16*b*, C-4*b*	2-6, 2-8, 2-14, C-1
Alcohol	3-2*b*, table 3-1	3-1, 3-2
Ammonia		
occurrence in military operations	10-5*b*	10-2
pathology	10-5*c*	10-2
physical properties	10-5*a*	10-2
prognosis	10-5*f*	10-2
symptoms	10-5*d*	10-2
treatment	10-5*e*	10-2
Amphetamines	3-1*c*, 3-4*c*	3-1, 3-3
Analeptics	5-9*b*	5-2
Analgesics	4-7*b*(2)(*c*)	4-3
Anemia	4-10*a*(2), 4-16*a*, 4-21*a*	4-10, 4-14, 4-16
Anoxia	6-7	6-2
Antibacterial therapy	4-7*b*, 4-8*h*	4-3, 4-9
Anticholinesterase	2-1*d*(1), table 3-1, 3-4*a*	2-1, 3-2, 3-3
Anticonvulsant drugs	2-4*c*(3), 2-6*c*, 2-8*a*(3) and *b*(3), 2-8*c*(3) and -9*e*, 2-9*h*, 2-12*c* and -14, 2-15*c* and -16*c*, app E	2-5, 2-8, 2-9, 2-11, 2-12, 2-13, 2-14, E-1
Antidote(s) for nerve agents	2-6—2-14	2-8
administration of	2-9, 2-11, 2-12, 2-15 and -16, 2-17 and -18, E-1	2-11, 2-12, 2-13, 2-14, 2-15, E-1
Antihistamines	5-9*b*	5-2
Anxiety reactions	table 3-1	3-2
Aplasia	4-16*a*	4-14
Arsenical vesicants		
characteristics	4-17	4-14
physical properties	4-17	4-14
physiological effects	4-18—4-21	4-14—4-16
treatment	4-17—4-21	4-14—4-16
Arsenoxides	4-17	4-14
Aspirin	7-16	7-4
Assisted ventilation		
administration	2-4*c*, 2-4*g*, 2-6*f*, 2-9*h*, 2-16*b*, 2-16*g*, 2-23*b*, 6-10, 10-5*e*	2-2, 2-6, 2-8, 2-12, 2-14, 2-15, 2-18, 6-2, 10-2
mechanical ventilator	2-16*g*	2-15
Atelectasis	5-4	5-1
Atropine sulfate. (*See also* Nerve agents.)		
administration by:		
autoinjector	2-10 and -11, 2-16*a*, 2-23*a*, E-2	2-12, 2-14, 2-18, E-1
atropine sulfate ophthalmic ointment (1 percent)	2-16*d*, 4-18*b*	2-15, 4-15
rate of absorption	2-8*b*	2-9

	Paragraph	Page
Atropine sulfate (*continued*)		
contraindications	5-9*b*	5-2
effects	2-7*b*, 2-8, 2-12	2-8, 2-9, 2-13
self-aid and buddy aid procedures	1-12, 2-11, 2-12, E-2, E-3	1-5, 2-12, 2-13, E-1, E-4
solution	4-7*b*	4-3
symptoms produced	2-8*c*	2-9
use with 2 PAM Cl	2-10, 2-15*b*, E-2*m* and -3*n*	2-12, 2-14, E-3
BAL ointment ((British anti-lewisite) dimercaprol)	4-19*d*(1), 4-21*c*	4-15, 4-16
Barbiturates	5-9*b*	5-2
Beclomethasone dipropionate	5-9*e*	5-2
Betamethasone	5-9*e*	5-2
Blankets, contaminated	4-3*b*, B-3, B-6	4-1, B-1, B-2
Bleach slurry	B-6 and -7	B-2
Blepharospasm	4-29*b*(3)(*a*), 7-4*a*(1)	4-18, 7-1
Blister agents. (*See also* Arsenical vesicants, Mustard, *and* Nitrogen mustard.)		
burns	4-1 and 4-6—4-31	4-1—4-22
characteristics	4-1 and -6	4-1
decontamination	4-3*b*, app B, app D	4-1, B-1, D-1
disposition of casualties		
cutaneous burns	4-31	4-19
eye injuries	4-29	4-18
evacuation of casualties	4-28*d*(1)(*b*), C-8	4-17, C-3
respiratory injuries	4-30	4-19
self-aid	4-2	4-1
Blood agents. (*See* Cyanogen chloride *and* Hydrogen cyanide.)		
Blister pack. (*See also* Nerve Agent Pyridostigmine Pretreatment Tablet Set.)	2-17 and -18, 2-20, 2-24*a*	2-15, 2-17, 2-18
Bromobenzylcyanide (CA)	7-1 and -3*c*, 7-4*c*, 7-5*c* and -7	7-1, 7-2, 7-3
Bronchiolar epithelium	5-4	5-1
Bronchitis	5-9*d*, 7-4*a*(1), 7-4*c*(1)	5-2, 7-1, 7-2
Bronchopneumonia	4-9*b*, 5-7 and -9*d*	4-10, 5-2
Buddy aid	1-12	1-5
Burns, treatment		
blister agents	4-7*b*, 4-8*f*, 4-12*c*, 4-18*b* and -19*d*	4-3, 4-8, 4-13, 4-15
incendiary agents	8-7*e*, 9-2 and -4*b*	8-3, 9-1
riot control agents	7-1	7-1
smokes	8-5*e*	8-2
Burow's solution	7-7*b*	7-3
BZ. (*See* Incapacitating agents.)		
Calamine lotion	7-7*b*	7-3
Cannabinols	3-1*c* and -2*b*, table 3-1, 3-4*c*	3-1, 3-2, 3-3
Carbon monoxide	10-2	10-1
poisoning		
diagnosis	10-2*e*	10-1
occurrence in military operations	10-2*b*	10-1
prognosis	10-2*h*	10-1
protection	10-2*f*	10-1
symptoms	10-2*d*	10-1
treatment	10-2*g*	10-1
Casualties		
assess dose of agent exposure	A-3*d*	A-2
decontamination	1-7, 1-10, 1-11, 2-6*d*, 2-9*d*, 2-16*f*, 3-3*b*, 4-6*b*, 4-8*d*, 4-19*b*, B-1, C-1, app D	1-2, 1-4, 1-5, 2-8, 2-11, 2-15, 3-2, 4-1, 4-6, 4-15, B-1, C-1, D-1
differential diagnosis	A-3*a*	A-2
emergency medical treatment	C-2—C-4	C-1
recognition of	app A	A-1
type of	A-2	A-1
Central nervous system		
depressants	3-1*c*	3-1

Central nervous system (*continued*)		
effects	2-4*a* and *c*, 2-5*a*	2-2, 2-6
stimulants	3-1*c*	3-1
Cerebral		
depression	4-10*b*(2)	4-10
edema	7-4*c*(1)	7-2
CG. (*See* Phosgene.)		
Chemical agents		
assess dose of agent exposure received	A-3*d*	A-2
classification	1-8	1-3
contamination	1-5, 1-10	1-2, 1-4
food and water	1-7	1-3
decontamination	1-7, 1-9 and -10	1-2, 1-4
definitions	1-4	1-2
detection	1-8	1-3
differential diagnosis	A-3*a*	A-2
exposed to	1-4, 1-6, 1-7*e*	1-1, 1-2, 1-3
means of delivery	1-5	1-2
military employment	1-2 and -4	1-1
persistence	preface	vi
physical characteristics	1-4	1-1
protective measures	1-7	1-2
riot control	preface	vi
routes of entry	1-3	1-1
signs and symptoms	1-7, A-3*c*	1-2, A-2
Chemical agent-tight containers	B-5	B-1
Chemical fire extinguishers	9-1	9-1
Chemical warfare agents	1-4, 1-8	1-1, 1-3
Chloral hydrate	3-4*a*	3-3
Chloroacetophenone (CN)	7-1 and -3*c*, 7-4*c*, 7-7	7-1, 7-2, 7-3
Chloropicrin (PS)	1-4*a*(3)	1-1
Chlorpromazine	3-4*b*	3-3
Choking agents. (*See* Phosgene.)		
Cholinesterase		
enzymes	2-4*a*, 2-19*a*	2-2, 2-16
inhibitor	2-1*a*, 2-4*a* and *b*, 2-8*a*, 3-4*a*	2-1, 2-2, 2-9, 3-3
CN and CA. (*See* Irritant agents.)		
Codeine	5-9*b*	5-2
Conjunctivitis	4-7*a*(1) and (2), 4-12*a*, 7-4*c*(1)	4-3, 4-12, 7-2
Contraindicated drugs	3-4*a*, 10-2*g*	3-3, 10-1
Convalescent care	5-10	5-3
Convulsions	2-16*c*, 6-5*a*	2-14, 6-1
Corneal involvement	4-7*a*(2)—(4) and *b*(2)(*d*), 4-7*b*(3), 4-12	4-3, 4-5, 4-12
Coughing	7-4*a*(1), 7-5*a* and *c*, 7-9, -13, and -15	7-1, 7-3, 7-4
Cricothyroid cannulation	9-5*b*(3)	9-2
Cricothyroidotomy	2-4*g*, 2-6*f*, 2-16*g*	2-6, 2-8, 2-15
CS. (*See* Irritant agents.)		
Curare	3-1*b*	3-1
CX. (*See* Phosgene oxime.)		
Cyanogen chloride (CK)		
characteristics	6-1 and -3*b*, 7-1	6-1, 7-1
diagnosis	6-5*b*, 6-6*b*	6-1, 6-2
pathology	6-4*b*	6-1
protection	6-2	6-1
treatment	6-8 and -9	6-2
Cyanosis	5-5, 6-5*b*, 6-10*c*	5-1, 6-1, 6-2
D-amphetamine	3-4*c*	3-3
Death	6-5*b*, 9-5*b*(1)	6-2, 9-2
Decontaminating	1-7, 1-10, app B, app D	1-2, 1-4, B-1, D-1

	Paragraph	Page
Decontaminating (*continued*)		
eyes	1-10*a*, 2-6*d*, 2-9*d*, 7-7*a*	1-4, 2-8, 2-11, 7-3
skin	1-10*a*, 2-6*d*, 2-9*d*, 2-16*f*, 3-3*b*, 4-2*b*	1-4, 2-8, 2-11, 2-15, 3-2, 4-1
Decontaminating kits, individual	app D	D-1
M258A1 Skin Decontamination Kit	1-10*a*	1-4
decontamination of the face, neck, ears, and other exposed skin	D-3	D-3
decontamination of the hands	D-2—D-3	D-1—D-5
M291, Skin Decontaminating Kit	1-10*a*	1-4
M295 Decontamination Packet, Individual Equipment (DPIE)	1-10*b*	1-4
Decontaminating procedures		
aprons	B-6*a*	B-2
casualties	1-11, 4-8*d*, C-1, app D	1-5, 4-6, C-1, D-1
clothing	1-10*b*, B-6	1-4, B-2
equipment (web, canvas, and leather)	B-6*b*	B-2
gloves	B-6*a*	B-2
litters	B-7	B-2
mask	B-6*b*	B-2
self	1-10, 4-26, app D	1-4, 4-17, D-1
DECON-1 WIPE	1-10	1-4
Depressant agents	3-1*b* and *c*, 3-4	3-1, 3-3
Dermatitis	7-4*a*(2), 7-4*c*(2) and -7*b*	7-2, 7-3
Dexamethasone sodium phosphate	5-9*e*	5-2
Dexamethasone sodium phosphate-neomycin ophthalmic ointment	4-7*b*(2)	4-3
Diagnosis of injury from toxic chemical agents	1-6, 1-8	1-2, 1-3
Diarrhea	4-10*b*, 4-16*d*, 4-21	4-10, 4-14, 4-16
Diazepam	2-6*c*, 2-8, 2-9*e*, 2-12 and -14, 2-15*c* and -16*c*	2-8, 2-9, 2-11, 2-13, 2-14
Dichloroarsines	4-17	4-14
Dichloroformoxime	4-23	4-17
Dimercaprol	4-19*d*	4-15
Diphenylaminochloroarsine (Adamsite) (DM)	7-9	7-4
Diphenylchloroarsine (DA)	7-9	7-4
Diphenylcyanoarsine (DC)	7-9	7-4
Disposal of contaminated clothing	4-3, C-5*d*	4-1, C-2
Disposition of casualties	4-5	4-1
D-lysergic acid diethylamide. (*See also* LSD.)	3-1*c*	3-1
DS2	B-7	B-2
Dyspnea	5-5, 5-9*a*, 6-5*b*, 7-4*a*(1), 7-5	5-1, 5-2, 6-1, 7-1, 7-3
Edema		
glottic	9-5*b*(1) and *c*(1)	9-2
pulmonary. (*See* Pulmonary edema.)		
Electrolyte solutions	4-10*e*, 4-16*d*	4-12, 4-14
Emphysema	5-4	5-1
Endotracheal tube	2-4*g*, 2-6*f*, 2-16*g*	2-6, 2-8, 2-15
Erythema, mustard	4-8	4-5
Ethyldichloroarsine	4-17*a*	4-14
Evacuation of chemical casualties	3-2, 5-9*a*, 7-7*c*, 9-5*d*, C-4*d*(5), C-8	3-1, 5-2, 7-4, 9-2, C-2, C-3
Eye lenses, decontamination	B-6*b*	B-2
Eyes		
classification of eye lesions	4-7*c*	4-5
decontamination	1-10, 2-9*d*, 2-16*f*, 4-7*b*, 8-7*a*, 9-5*d*, app D	1-4, 2-11, 2-15, 4-3, 8-3, 9-2, D-1
effects of agents. (*See* specific agents.)		
injuries	1-7 and -8, 1-9, 4-29	1-3, 1-4, 4-18
treatment of eye injuries	2-9*c*, 2-16*d*, 4-7*b*, 4-12*c*, 4-17, 7-7*a*, 8-5*e*(1)	2-11, 2-15, 4-3, 4-13, 4-14, 7-3, 8-2

	Paragraph	Page
Fibrosis, pulmonary	5-9*e*	5-3
Firebomb		
attack	9-5*c*	9-2
casualties	9-5*c*(1)	9-2
protection	9-5*c*(2)	9-2
treatment	9-5*a*	9-2
Fire hazards	1-2*d*, 10-6	1-1, 10-2
Flamethrower		
attack	9-5*b*	9-2
casualties	9-5*b*(1)	9-2
protection	9-5*b*(2)	9-2
treatment	9-5*b*(3)	9-2
Fluocinolone acetonide	7-7*b*	7-3
Fluorescein	4-18, 4-29*b*(3)(*a*)	4-14, 4-18
Flurandrenolone	7-7*b*	7-3
Food, contaminated	1-7, 2-5*a*, 2-7*c*, 2-16*e*, 4-1*d*, 4-10*b*(1), 4-10*d*	1-3, 2-6, 2-9, 2-15, 4-1, 4-10, 4-12
G-agents. (*See* Nerve agents.)		
Genitalia, blister agent burns	4-31*i*	4-21
Gloves, protective	1-7, 4-3, 7-2, B-5*a*, B-6*a*, D-1	1-3, 4-1, 7-1, B-1, B-2, D-1
Granulocytopenia	4-16	4-14
Hands, blister agent burns	4-31*g*	4-20
HC mixture. (*See* Smokes.)		
HD. (*See* Mustard.)		
Headache	6-5*a*, 7-5*c*, 7-13	6-1, 7-3, 7-4
Hemoconcentration	4-10, 4-21	4-10, 4-16
Hemorrhagic diathesis	4-16	4-14
HN1. (*See* Nitrogen mustards.)		
HN3. (*See* Nitrogen mustards.)		
Hydrogen cyanide (AC) (hydrocyanic acid)		
characteristics	6-1 and -3*a*	6-1
diagnosis	6-5, 6-6	6-1, 6-2
effects	6-3*a*	6-1
pathology	6-4*a*	6-1
prognosis	6-7	6-2
protection	6-2	6-1
self-aid	6-8	6-2
treatment	6-10	6-2
Hydrogen sulfide		
occurrence in military operations	10-4*b*	10-2
pathology	10-4*c*	10-2
physical properties	10-4*a*	10-2
symptoms	10-4*d*	10-2
treatment	10-4*e*	10-2
Hypovolemic shock	4-10*b*	4-10
Hypoxemia	5-9*c*	5-2
Identity of chemical agents	1-8	1-3
Incapacitating agents (BZ)	3-1	3-1
decontamination	3-3*b*	3-2
diagnosis	3-2	3-1
first aid	3-3*c*	3-2
protection	3-3*a*	3-2
treatment	3-4	3-3
types	3-1*a* and *c*	3-1
Incendiary agents		
combustible hydrocarbons	9-5	9-2
general	9-1	9-1
magnesium	9-3	9-1
self-aid	9-4*a*	9-1
treatment of burns	9-2 and -4*b*, 9-5	9-1, 9-2
white phosphorus	9-4	9-1

	Paragraph	Page
Indoles	3-2, 3-4*b*	3-1, 3-3
Injector, atropine. (*See* Atropine.)		
Insecticides	2-1*d*	2-1
Intravenous fluids	9-5*d*(6)	9-3
Intubation	9-5*b*(3)	9-2
Iritis	4-7*a*(3), 4-12*b*, 4-18*a*, 4-29*b*, 7-7*a*	4-3, 4-13, 4-14, 4-18, 7-3
Irritant agents		
characteristics	7-3	7-1
diagnosis	7-5	7-3
physiological effects	7-4	7-1
prognosis	7-8	7-4
protection	7-2	7-1
self-aid	7-6	7-3
treatment	7-7	7-3
Kits		
Mark I Nerve Agent Antidote Kit	2-6, 2-9, 2-10 and -11, 2-15—18, 2-19*a*, 2-20*b*, app E	2-8, 2-11, 2-12, 2-14, 2-16, 2-17, E-1
M256 Chemical Agent Detector Kit	1-8	1-3
M258A1 Skin Decontamination Kit	1-10, B-6*b*, D-3	1-4, B-2, D-3
M291 Skin Decontaminating Kit	1-10*a*, B-6*b*, D-2	1-4, B-2, D-1
Lacrimators	6-3*b*, 7-1, -3*c*, and -4, 7-9	6-1, 7-1, 7-4
Lesions. (*See* Blister agents.)		
Leukopenia	4-10*e*	4-12
Lewisite (L) (chlorovinyldichloroarsine)	1-4*a*, 1-8, 4-1, 4-17	1-2, 1-4, 4-1, 4-14
Lifesaving measures	2-8*a*, 2-9*h*	2-9, 2-12
Liquid arsenical vesicants, effects of	1-4, 1-8, 4-17—4-22	1-2, 1-3, 4-14—4-16
Liquid nerve agent, effects of	2-4*d*	2-6
Litters		
care	B-7	B-2
decontamination	B-7	B-2
protection	B-7	B-2
Lower extremities	4-31*h*	4-21
LSD	3-1*c*, 3-2*c*, 3-4*b*—*c*	3-1, 3-2, 3-3
Lung irritants. (*See* Phosgene.)		
Magnesium (MG)	9-3	9-1
Marihuana	3-2*b*, table 3-1	3-1, 3-2
Masking	1-12*b*, 2-3*b*, 2-6*a* and -7, 2-9*a*, 2-11*a*, 2-12*b*, 3-3*a*, 4-25, 7-2, 7-10 and -13, 9-1*b*, 9-5*d*, B-4*a*, C-8	1-5, 2-1, 2-8, 2-11, 2-12, 2-13, 3-2, 4-17, 7-1, 7-4, 9-1, 9-2, B-1, C-3
Masking the odor of chemical agents	1-6*a*	1-2
Mass casualties	C-1	C-1
Mechanical ventilator	2-16*g*	2-15
Mechanism of action, nerve agents	2-4*a*	2-2
Medical treatment facility (MTF)	2-15, 4-3*b*	2-14, 4-1
Mental depression	7-5*c*, 7-13	7-3, 7-4
Metal decontamination	B-7*b*(1)(*c*)	B-2
Methemoglobin	10-3*c*	10-1
Methemoglobinemia	6-10*c*	6-2
Methyldichloroarsine	4-17	4-14
Methylprednisolone	5-9*e*(2)(*c*)	5-3
Military use of chemical agents	1-2, 1-4*b*	1-1, 1-2
Miosis	2-3*a*, 2-4*c*, 2-4*d*, 2-5*b*, 2-9*c*, 2-16*d*, 4-12*a*, 4-18, 4-29*b*(2)(*a*)	2-1, 2-2, 2-6, 2-8, 2-11, 2-15, 4-12, 4-14, 4-18
Mission-oriented protective posture (MOPP) level	1-7, 2-8*c*, 2-20*d*, B-4	1-2, 2-9, 2-17, B-1
Morphine	4-10*b*, 9-5*a*	4-12, 9-2
MRE pouches	4-10*d*	4-12
Muscarinic		
effects	2-4*c*(3)(*a*), 2-5*a*, 2-8*a*(1), 2-8*c*(1)(*d*), 2-16*a*	2-5, 2-8, 2-9, 2-11, 2-14

	Paragraph	Page
Muscarinic (*continued*)		
signs and symptoms	2-4*a*, table 2-1, 2-4*c*(3)(*b*), 2-5*a*, 2-13, 2-15*a*(1)	2-2, 2-3, 2-5, 2-8, 2-13, 2-14
Mustard (HD)		
burns	4-7*b*(3)	4-5
characteristics	1-4*a*(2), 4-6*a*	1-2, 4-1
conjunctivitis	4-7*b*(2)	4-3
decontamination	1-4, 1-10, 1-11, 4-7*b*(1), 4-8*d*	1-1, 1-4, 1-5, 4-3, 4-6
effects on the eye	1-7, 4-7	1-2, 4-2
ingestion	4-10*e*(2)	4-12
lesions of eyes	4-7*b*(2), 4-7*b*(3), 4-29*c*	4-3, 4-5, 4-19
pathology	4-7*a*, 4-8—4-10	4-2, 4-5—4-10
persistence	1-4, 4-6*b*	1-1, 4-2
prognosis	4-7*a*	4-2
sensitivity	4-29	4-18
symptoms	1-6 and -7, 4-7*a*, 4-8, 4-9, 4-10*b*	1-2, 4-2, 4-5, 4-9, 4-10
treatment	4-7*b*, 4-12*c*, 4-18*b*, 4-29	4-3, 4-13, 4-15, 4-18
vapor	1-2, 1-13, 4-6	1-1, 1-5, 4-1
M8 Detector Paper	1-8*a*	1-3
M9E1 Chemical Agent Detector Paper	1-8*a*	1-3
M17 series protective mask carrier	1-10	1-4
M24 and M25 series protective mask	1-10	1-4
M256 Chemical Agent Detector Kit	1-8*c*	1-4
M258A1 Skin Decontamination Kit	1-10*a*, 4-8*d*, D-3	1-4, 4-6, D-3
M291 Skin Decontaminating Kit	1-10, D-2	1-4, D-1
M295, Decontaminating Packet, Individual Equipment	1-10*b*	1-5
Nausea	6-5*a*, 7-1 and -4*a*(1), 7-9, -13, and -15	6-1, 7-1, 7-4
Neostigmine	3-4*a*	3-3
Nerve Agent Antidote Kit, Mark I, procedures for administering	2-9—2-16, app E	2-11—2-14, E-1
Nerve Agent Pyridostigmine Pretreatment Tablet Set (NAPP)	2-17—2-24	2-15—2-18
Nerve agents	1-4, 2-1 and -3	1-1, 2-1
absorption	1-6, 1-10, 2-3*a*, 2-7, 2-8*b*, 2-9	1-2, 1-4, 2-1, 2-8, 2-9, 2-11
cause of death	2-4*c*, 2-4*g*	2-2, 2-6
characteristics	1-4, 2-1—2-24	1-2, 2-1—2-18
convulsions	2-4*c*, 2-5*b*, 2-12 and -14, 2-15*c*, -16*a*, and -16*c*	2-2, 2-8, 2-13, 2-14
cumulative effects of repeated exposure	2-4*a*, 2-4*f*	2-2, 2-6
decontamination	1-9 and -10, 2-2 and -3*c*, 2-9*d*, 2-16*f*, app D	1-4, 2-1, 2-11, 2-15, D-1
diagnosis	1-6, 1-13, 2-5	1-2, 1-5, 2-6
effects of vapor	2-4*c*	2-2
first aid	1-12	1-5
buddy aid	1-12*b*, 2-5*b*, 2-9, 2-11, 2-12, E-3	1-5, 2-8, 2-11, 2-12, 2-13, E-4
self-aid	1-12*a*, 2-5*b*, 2-9, 2-11, 2-12, E-2	1-5, 2-8, 2-11, 2-12, 2-13, E-1
medical treatment	1-13, 2-1*d*, 2-4, 2-6, 2-8—2-16	1-5, 2-1, 2-2, 2-8, 2-9—2-14
physiological effects	1-4, 2-1*a*	1-1, 2-1
pretreatment	2-17—2-24	2-15—2-18
prevention	2-3*b*, 2-6 and -7, 2-12	2-1, 2-8, 2-13
protection	2-3*b*, 2-3*d*, 2-6*a*—2-9, 2-19*a*	2-1, 2-2, 2-8—2-11, 2-16
V-agent	1-4, 2-4*a*	1-1, 2-2
Nicotinic effects	2-4*a*, 2-4*c*	2-2, 2-5
Nitrogen mustard (HN)		
characteristics	4-11	4-12
physiological effects	1-4, 4-12—4-16	1-1, 4-12—4-14
treatment	4-12—4-16	4-12—4-14

	Paragraph	Page
Nitrous fumes		
diagnosis	10-3*e*	10-2
occurrence in military operations	10-3*b*(1) and (2)	10-1
physical properties	10-3*a*	10-1
physiological effects	10-3*c*	10-1
prognosis	10-3*g*	10-2
protection	10-1*c*	10-1
symptoms	10-3*d*	10-2
treatment	10-3*f*	10-2
Nonpersistent		
chemical agent	preface, 5-3, 6-1 and -3*b*	vi, 5-1, 6-1
nerve agent	2-2	2-1
Normal saline solution	7-4*a*(2)	7-2
Objectives of health service support	C-2	C-1
O-chlorobenzylidene malononitrile (CS)	7-1 and -3*a*, 7-4—7-6	7-1, 7-1—7-3
Ophthalmic ointment, atropine	4-18*b*	4-15
Opiates	4-16*d*	4-14
Oral replacement of body fluids	9-5*d*	9-2
Organophosphates	1-1*b*, 2-1*d*	1-1, 2-1
Oxygen therapy	2-6*f*, 2-16*g*, 5-9*c*, 6-10, 10-2*g*	2-8, 2-15, 5-2, 6-2, 10-1
Parasympathomimetic effects	4-10*b*(2)	4-10
Persistent		
chemical agent	preface	vi
nerve agent	preface	vi
Personal decontamination	1-10, 4-26	1-4, 4-17
Petroleum oil smoke. (*See* Smokes.)		
Phenothiazine-type compounds	3-1*c*(1)(*b*), 3-4*a*	3-1, 3-3
Phenyldichloroarsine (PD)	4-22	4-16
Phosgene (CG)		
characteristics	1-4, 5-3	1-1, 5-1
diagnosis	5-6	5-1
general	5-1	5-1
pathology	5-4	5-1
protection	5-2	5-1
self-aid	5-8	5-2
symptoms	5-5	5-1
treatment	5-8—5-10	5-2—5-3
Phosgene oxime (dichloroformoxime) (CX)		
characteristics	4-23	4-17
physiological effects	1-4, 4-1, 4-24	1-1, 4-1, 4-17
protection	4-25	4-17
treatment	4-26 and -27	4-17
Phosphoric acid derivatives	2-1*a*	2-1
Photophobia	4-12*a*, 4-29, 7-4*c*(1)	4-12, 4-18, 7-2
Physostigmine (salicylate)	2-1*a*, 3-4*a*	2-1, 3-3
Pneumonitis, chemical	4-14*b*	4-14
Pralidoxime chloride (2 PAM Cl)	2-8*a*(2) and *b*(2), 2-8*c*(2) and -9*f*, 2-10, 2-15*b*	2-9, 2-11, 2-12, 2-14
Prednisolone	5-9*e*(1)(*b*), 5-9*e*(2)(*c*)	5-2, 5-3
Prevention of poisoning	2-3, 2-6 and -7	2-1, 2-8
Protective		
mask		
conditions for	1-7, 2-3*b*, 2-6 and -7, 2-9, 2-11, 2-20*d*, 3-3*a*, 4-2, 4-25, 5-8, 6-2, 6-8*b*, 7-2, 7-6, 7-10 and -15, 8-2, 8-4*d*, -5*d*, and -6*d*, 8-7*d*, 10-6	1-2, 2-1, 2-8, 2-11, 2-12, 2-17, 3-2, 4-1, 4-17, 5-2, 6-1, 6-2, 7-1, 7-3, 7-4, 8-1, 8-2, 8-3, 10-2
limitations	4-4*a*, 9-1, 10-1*c*, 10-6*b*	4-1, 9-1, 10-1, 10-2
overgarment	1-12*b*, 2-3*d*, 2-6*a*, 2-9*a*, 4-4*b*, 7-2	1-5, 2-2, 2-8, 2-11, 4-1, 7-1
Pruritus	7-7*b*	7-3

	Paragraph	Page
Pulmonary		
edema	4-14*a*, 4-20*a*, 4-21*c*, 5-4, -5, and -6, 5-9*a*, 6-4 and -5*b*, 7-4*c*(1)	4-13, 4-15, 4-16, 5-1, 5-2, 6-1, 7-2
fibrosis	4-9, 5-9*e*(2)(*c*)	4-9, 5-3
parenchyma	4-30*h*	4-19
Pyridostigmine	2-1*a*, 2-17—2-24, 3-4*a*	2-1, 2-15—2-18, 3-3
Reactions of agents with water	1-5	1-2
Reception of contaminated casualties basic plan	C-1, -3, and -4	C-1
Respiratory system, effects on	1-6, 2-4*a* and *c*, 2-5, 4-9, 4-14, 4-20, 4-30, 9-5*b*(3)	1-2, 2-2, 2-6, 4-9, 4-13, 4-15, 4-19, 9-2
Resuscitation. (*See* Assisted ventilation *and* Mechanical ventilator.)		
Rhinorrhea	7-5*a*	7-3
Riot control agents	7-1—7-17	7-1—7-4
Rubber gloves	7-2*a*	7-1
Saprophytic bacteria	4-8*b*(3)	4-6
Sarin (GB)	1-4*a*, 2-1*b*	1-2, 2-1
Sedatives	4-16*d*, 4-19*d*, 5-9*b*	4-14, 4-15, 5-2
Self-aid		
blister (vesicant) agents	4-2	4-1
cyanogen chloride (CK)	6-8*b*	6-2
hydrogen cyanide (AC)	6-8*a*	6-2
mustard (HD)	4-2, 4-7*b*	4-1, 4-3
mustard (HN)	4-12	4-12
nerve agents	2-1—2-7*c*, 2-15 and -16, E-2	2-1—2-9, 2-14, E-1
phosgene	5-8	5-2
zinc oxide (HC) mixtures	8-4*d*	8-2
Shipboard operations	B-5*b*	B-1
Signs and symptoms of toxic agents	1-7	1-2
Silver sulfadiazine burn cream	4-8*f*	4-8
Skin		
blister agent lesions	1-4, 4-1, 4-8, 4-13, 4-19, 4-24, 4-31	1-1, 4-1, 4-5, 4-13, 4-15, 4-17, 4-19
decontamination	1-10, 3-3*b*, 4-2, 4-7*b*, 4-8*d*, 4-13*c*, 4-26, 7-2, 7-6, 8-6*d*, D-1	1-4, 3-2, 4-1, 4-3, 4-6, 4-13, 4-17, 7-1, 7-3, 8-2, D-1
Smokes, agents used		
HC mixtures	8-1 and -4	8-1
pathology	8-4*b*	8-1
petroleum oil (fog oil (SGF2))	8-1*a* and -3	8-1
physical properties	8-3*a*	8-1
physiological properties	8-3*b*	8-1
prognosis	8-4*f*	8-2
properties	8-4*a*	8-1
self-protection	8-4*d*	8-2
symptoms	8-4*c*	8-1
treatment	8-4*e*	8-2
sulfur trioxide-chlorosulfonic acid (FS)	8-5	8-2
pathology	8-5*b*	8-2
prognosis	8-5*f*	8-2
properties	8-5*a*	8-2
self-aid	8-5*d*	8-2
symptoms	8-5*c*	8-2
treatment, eye and skin	8-5*e*	8-2
titanium tetrachloride (FM)	8-1*a*, 8-6	8-1, 8-2
pathology	8-6*b*	8-2
prognosis	8-6*f*	8-3
properties	8-6*a*	8-2
self-aid	8-6*d*	8-2
symptoms	8-6*c*	8-2
treatment	8-6*e*	8-3

	Paragraph	Page
white phosphorus (WP)	8-1*a*, 8-7	8-1, 8-3
pathology	8-7*b*	8-3
prognosis	8-7*f*	8-3
properties	8-7*a*	8-3
self-aid	8-7*d*	8-3
symptoms	8-7*c*	8-3
treatment	8-7*e*	8-3
zinc chloride	8-1*a*	8-1
pathology	8-4*b*	8-1
properties	8-1 and -4*a*	8-1
protection	8-2	8-1
self-aid	8-4*d*	8-2
symptoms	8-4*c*	8-1
treatment	8-4*e*	8-2
Sneezing	7-9, -13, and -15	7-4
Sodium		
bicarbonate	7-4*a*(2)	7-2
carbonate	7-4*a*(2)	7-2
nitrite injections	6-10*c*	6-2
sulfacetimide	4-7*b*, 4-12	4-3, 4-12
thiosulfate	6-10	6-2
Soman (GD)	1-4, 2-1*b*	1-1, 2-1
Steroid treatment	5-9*e*	5-2
Stimulants	3-1*c*(2)	3-1
Sulfur trioxide-chlorosulfonic acid solution (FS)	8-1, 8-5	8-1, 8-2
Synechia	4-18*a*	4-14
Tabun (GA)	1-4*a*, 2-1*b*	1-2, 2-1
Tactical use of chemical agents	1-2, 1-5	1-1, 1-2
Tear agents (lacrimators)	7-1	7-1
Thermite (TH)	9-2	9-1
Time course of nerve agent effects	table 2-2	2-7
Titanium tetrachloride (FM)	8-1, 8-6	8-1, 8-2
Topical corticosteroid	7-7*b*	7-3
Tracheitis	7-4*a*(1)	7-1
Tracheotomy	9-5*b*	9-2
Training agents. (*See also* O-chlorobenzylidene malononitrile (CS), Chloroacetophenone (CN), *and* Bromobenzylcyanide (CA)).	7-1	7-1
Treatment of injuries caused by chemical agents. (*See* specific agents.)		
Triage	C-4*b*	C-1
Triamcinolone acetonide	7-7*b*	7-3
Trimethobenzamide hydrochloride	7-16	7-4
protective measures	1-7	1-2
riot control agents	7-6	7-3
sulfur trioxide-chlorosulfonic acid (FS)	8-5*d*	8-2
titanium tetrachloride (FM)	8-6	8-2
vomiting agents	7-15	7-4
white phosphorus (WP)	8-7, 9-4	8-3, 9-1
Unit medical support	C-1	C-1
Urticants. (*See* Phosgene oxime.)		
V-agents	1-4, 2-1*b*	1-1, 2-1
Vapor effects	1-3 and -4, 2-3*a*, 2-4, 2-5*a*, 2-7*c*, 2-9*f*, 4-9, 4-14, 4-24, 4-31, 6-3, 7-4	1-1, 2-1, 2-2, 2-6, 2-9, 2-11, 4-9, 4-13, 4-17, 4-19, 6-1, 7-2
Vertigo	6-5*a*	6-1
Vesicants. (*See* Blister agents.)		
Vomiting agents		
characteristics (properties)	1-6, 7-11	1-2, 7-4
diagnosis	1-6, 1-13, 7-14	1-2, 1-5, 7-4
effects	7- 9, -12, and -13	7-4

	Paragraph	Page
Vomiting agents (*continued*)		
odor	1-6	1-2
pathology	7-12	7-4
prognosis	7-17	7-4
protection	1-7, 7-10	1-2, 7-4
self-aid	1-12, 7-15	1-5, 7-4
symptoms	1-6, 7-13	1-2, 7-4
treatment	1-13, 7-16	1-5, 7-4
VX	1-4, 2-1*b*	1-1, 2-1
Water, contamination	1-7*e*, 2-7*c*, 2-16*e*, 4-1*d*, 4-10*b*	1-3, 2-9, 2-15, 4-1, 4-10
Weather, effects	2-10*c*, 4-6*b*, 4-8, B-2	2-12, 4-2, 4-5, B-1
Web equipment, decontamination	B-6*b*(2)	B-2
Wet Bulb Globe Temperature (WBGT) Index	1-7*f*	1-3
White phosphorus (WP)	8-7, 9-4	8-3, 9-1
treatment	8-7, 9-4	8-3, 9-1
World War I statistics	4-7*a*, 4-9*a*(2), 4-28*b*, 5-7	4-2, 4-9, 4-17, 5-2
World War II experience	4-28*c*	4-17
Zinc chloride	5-9*e*, 8-1 and -4	5-2, 8-1
pathology	8-4*b*	8-1
properties	8-1 and -4*a*	8-1
protection	8-2	8-1
self-aid	1-12*a*, 8-4*d* and -5*d*, 8-7*d*	1-5, 8-2, 8-3
treatment	8-4—8-7	8-2—8-3